Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00944905 · ClinicalTrials.gov registry record · Phase 1
Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT00944905 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 46 participants.
The verdict
NCT00944905, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if MDX-1203 is safe for the treatment of renal cell carcinoma or non-hodgkin's lymphoma.
Interventions
- BIOLOGICAL MDX-1203
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2009-07 |
| Est. Completion | 2012-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00944905
The ClinicalTrials.gov registry entry for NCT00944905 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MDX-1203 is the first listed.
NCT00944905 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00944905 about?
NCT00944905 is a clinical study titled "Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)". The purpose of this study is to determine if MDX-1203 is safe for the treatment of renal cell carcinoma or non-hodgkin's lymphoma.
What is the current status of trial NCT00944905?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2009-07. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00944905?
The interventions under investigation include: MDX-1203 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00944905?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.